eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2021
vol. 46
 
Share:
Share:
abstract:
Case report

Nivolumab in two cases of refractory mycosis fungoides erythroderma

Ewa Chmielowska
1, 2

  1. Oncology Center in Bydgoszcz, Poland
  2. Specialistic Oncologic Hospital NU-MED Tomaszów Mazowicki, Poland
(Cent Eur J Immunol 2021; 46 (4): 535-538)
Online publish date: 2021/12/03
View full text Get citation
 
PlumX metrics:
Mycosis fungoides (MF) is the most common subtype of primary cutaneous T cell lymphoma (CTCL). The erythrodermic form (T4) especially impairs health-related quality of life (HR-QoL), making patients often incapable of self-care. Mycosis fungoides and Sézary syndrome (SS) are immunogenic neoplasms and can be recognized by the patient’s immune system. The disease is chronic and immunotherapy allows for long-term control of CTCL. The paper presents a description of 2 cases of nivolumab use in the salvage treatment of erythroderma in the course of refractory mycosis fungoides. Nivolumab was used as emergency treatment, and previously patients exhausted the available treatment options. The discussed cases confirm the effectiveness of immunotherapy in the treatment of primary cutaneous T cell lymphomas. The applied treatment achieved the effect of more than one year of response (15 months), as well as a significant benefit in terms of subjective and objective quality of life. The effect was mainly related to the condition of the skin. The use of the PD-1 checkpoint inhibitor allowed for over 12 months of control in advanced, refractory and heavily pretreated cutaneous lymphoma, and was very well tolerated. More research is needed on the use of such inhibitors in the treatment of cutaneous lymphomas.
keywords:

nivolumab, refractory disease, mycosis fungoides erythroderma

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.